HTG2014-Section-Header-publications

Publications

Explore HTG publications
with our new search tool. Launch Now

Categories

Reset Categories

Filter by Topics

AACR2023 ALK aplastic anemia AA Autoimmune Disorder B-cell lymphoma Biology of neoplasia Biomarkers Bladder Cancer bone Brain Breast Cancer CD3 Cells Cerebrospinal Fluid clinical trial cold tumor Colorectal cancer Comparison study CXCL12 Cytokines Developmental Immunotherapy Developmental Therapeutics Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug sensitivity EHE cancer Encephalophy EPCORE NHL-1 ERBB3 FFPE Gene Expression Profiling Genetic Polymorphism Heart Histone Deacetylase Inhibitors hot tumor HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTP Immune Checkpoint Inhibitors Immune Response Immune-related Colitis Immuno-Oncology IMMUNOSARC Immunotherapy IOA- 244 IRP Kidney Liposarcoma liver Liver Lung lungs lymphoma Lymphoma Melanoma melanoma Microenvironment miRNA miRNA WTA Molecular Characterization Nash and Fibrosis Natural Killer Cells Nestin+ Neurologic non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL OBP Oesophageal Adenocarcinoma Oral cancer oral squamous cell carcinoma OSCC PanB Pancreas pancreatic ductal adenocarcinoma PDAC Parkinson's Disease Pathway Analysis PDX model PI3K inhibitors PIP Plasma Platform Comparison Programmed cell death protein 1 Prostate qNPA qPCR Radioimmunotherapy Rheumatoid Arthritis Sarcoma Serum Signatures soft tissue sarcoma Sub-typing Survival plots T cells Thymic Carcinoma Tislelizumab TME Transplantation Treatment Outcome Treatment Targets Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Zanubrutinlb
Reset Filter Reset All

2020

Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.

Moura, D. S., et al. Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study. J  Clin Oncol 38: 2020 (suppl; abstr 11546). DOI: 10.1200/JCO.2020.38.15_suppl.11546

Download jpg 6.0MB
View External Link

Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma

Xu, J., et al. Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma. J Clin Oncol 38: 2020 (suppl; abstr 3115). 

Download jpg 6.4MB
View External Link

Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era

Hwang, M., et al. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era.  Poster session presented at: United Sstates and Canadian Academy of Pathology (USCAP) 109th Annual Meeting 2020 FEB 29- MAR 5, Los Angeles, CA

Download pptx 4.4MB

Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial.

Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials.

Lenz, A., et al. CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials.  Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

2019

Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastaticliposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Int

Valverde, C., et al. Translational  Study Associated to a Phase II Study Evaluating the Activity of Pazopanib in Patients (pts) with Advanced Metastatic Liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.  Poster session presented at: American Society of Clinical Oncology (ASCO) Annual meeting,  2019 Jun 3; Chicago, IL.

Download ppt 1.1MB

The Anti-CD25 Antibody-Drug conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity both as Single Agent and in Combination in Lymphoma Cell Lines

Spriano, F. et al. The Anti-CD25 Antibody-Drug Conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity Both as Single Agent and in Combination in Lymphoma Cell Lines. Poster presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.134_2630

Download pdf 2.4MB
View External Link

Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.

Valverde Morales, C. M., et al. Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.  American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL

View External Link

Page last updated May 22, 2023